1.46
price down icon5.81%   -0.09
after-market 시간 외 거래: 1.43 -0.03 -2.05%
loading
전일 마감가:
$1.55
열려 있는:
$1.5
하루 거래량:
2.90M
Relative Volume:
0.56
시가총액:
$316.12M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.6887
EPS:
-2.12
순현금흐름:
$-239.25M
1주 성능:
-13.10%
1개월 성능:
-25.13%
6개월 성능:
-47.86%
1년 성능:
-67.34%
1일 변동 폭
Value
$1.39
$1.5019
1주일 범위
Value
$1.39
$1.70
52주 변동 폭
Value
$1.32
$4.45

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
명칭
Allogene Therapeutics Inc
Name
전화
(650) 457-2700
Name
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
직원
361
Name
트위터
@AllogeneTx
Name
다음 수익 날짜
2025-03-04
Name
최신 SEC 제출 서류
Name
ALLO's Discussions on Twitter

ALLO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.46 316.12M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-14 업그레이드 Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 재개 Oppenheimer Outperform
2024-05-31 개시 Piper Sandler Overweight
2024-01-05 다운그레이드 Guggenheim Buy → Neutral
2024-01-05 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 개시 Citigroup Buy
2023-06-26 재개 Oppenheimer Outperform
2023-03-21 개시 Bernstein Mkt Perform
2023-01-24 업그레이드 JP Morgan Neutral → Overweight
2023-01-06 업그레이드 Robert W. Baird Neutral → Outperform
2022-12-12 다운그레이드 BofA Securities Buy → Underperform
2022-08-10 다운그레이드 Raymond James Outperform → Mkt Perform
2022-07-15 업그레이드 Goldman Neutral → Buy
2022-06-03 개시 Robert W. Baird Neutral
2022-02-28 재확인 B. Riley Securities Buy
2021-10-20 개시 Cowen Outperform
2021-10-08 다운그레이드 Goldman Buy → Neutral
2021-10-08 다운그레이드 Stifel Buy → Hold
2021-09-23 업그레이드 Raymond James Mkt Perform → Outperform
2021-06-21 재개 Jefferies Buy
2021-05-20 업그레이드 Truist Hold → Buy
2021-05-14 개시 B. Riley Securities Buy
2021-01-26 업그레이드 Stifel Hold → Buy
2020-12-10 재개 H.C. Wainwright Buy
2020-11-24 개시 BofA Securities Buy
2020-10-23 개시 RBC Capital Mkts Outperform
2020-06-01 다운그레이드 Raymond James Outperform → Mkt Perform
2020-05-29 재확인 H.C. Wainwright Buy
2020-05-19 업그레이드 ROTH Capital Neutral → Buy
2020-05-15 업그레이드 Guggenheim Neutral → Buy
2020-05-14 재확인 H.C. Wainwright Buy
2020-05-14 다운그레이드 SunTrust Buy → Hold
2020-04-13 개시 SunTrust Buy
2020-03-13 개시 H.C. Wainwright Buy
2020-03-05 개시 Stifel Hold
2020-02-24 개시 Berenberg Hold
2019-12-18 개시 JMP Securities Mkt Outperform
2019-11-04 개시 Canaccord Genuity Buy
2019-08-09 개시 BTIG Research Buy
2019-06-05 개시 ROTH Capital Neutral
2019-05-31 개시 Guggenheim Neutral
2019-05-23 개시 Stifel Hold
2019-03-29 개시 Piper Jaffray Overweight
모두보기

Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스

pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics CEO sells $91,469 in stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com

Mar 18, 2025
pulisher
Mar 17, 2025

7th Annual Allogeneic Cell Therapies Summit - pharmaphorum

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025
pulisher
Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens Capital Markets Upgrades Allogene Therapeutics (ALLO) - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Yahoo

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlight - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene stock upgraded at Citizens post Q4 (ALLO:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics: Q4 Earnings Snapshot - The Wilton Bulletin

Mar 14, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Inc Q4 Loss Per Share $0.28 -March 13, 2025 at 05:32 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Estimates; Revenue Falls Short - GuruFocus.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

ALLOGENE THERAPEUTICS Earnings Results: $ALLO Reports Quarterly Earnings - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics: Q4 Earnings Snapshot -March 13, 2025 at 05:05 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 08, 2025

Allogene Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 05, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - Yahoo Finance

Mar 05, 2025
pulisher
Mar 05, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire

Mar 05, 2025
pulisher
Mar 03, 2025

Foresight Diagnostics expands Allogene partnership - BizWest

Mar 03, 2025
pulisher
Mar 03, 2025

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

When Will Allogene Reveal Its CAR T Progress? Key Earnings Date Set - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Allogene Therapeutics Schedules Conference Call and Webcast for Q4 and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq

Mar 03, 2025
pulisher
Feb 27, 2025

Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia - The Malaysian Reserve

Feb 27, 2025
pulisher
Feb 27, 2025

Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise - MSN

Feb 27, 2025
pulisher
Feb 26, 2025

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities (NASDAQ:ALLO) - Seeking Alpha

Feb 26, 2025
pulisher
Feb 26, 2025

Allogene Expands Partnership With Foresight Diagnostics To Advance Cema-Cel Development Globally - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Allogene Therapeutics Announces Participation in March Investor Conference - The Manila Times

Feb 26, 2025

Allogene Therapeutics Inc (ALLO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
자본화:     |  볼륨(24시간):